aa	amino acid;
aAPC	artificial antigen-presenting cell;
AAV	adeno-associated virus
ACT	adoptive cell therapy;
ADCC	antibody-dependent cell-mediated cytotoxicity;
AICD	activation-induced cell death;
ALL	acute lymphoblastic leukemia;
BBB	blood-brain barrier;
CAR	chimeric antigen receptor;
CAR-NK	CAR-modified NK cells;
CHL	classical Hodgkin’s lymphoma;
CLL	chronic lymphocytic leukemia;
CRS	cytokine release syndrome;
CTL	cytotoxic T lymphocytes;
DLBCL	diffuse large B-cell lymphoma;
DLL1	Delta-like-1;
EBs	embryoid bodies;
EGFR	epidermal growth factor receptor;
ES	embryonic stem cells;
FasL	Fas ligand;
GM-CSF	granulocyte macrophage colony stimulating factor;
GMP	good manufacturing practice;
GvHD	graft-versus-host disease;
HLA-I	human leukocyte antigen-I;
HSC	hematopoietic stem cells;
ICANS	immune effector cell-associated neurotoxicity syndrome;
IFN-γ	interferon-γ;
IL	interleukin;
iPSCs	induced pluripotent stem cells;
ITAM	immunoreceptor tyrosine-based activation motif;
KIRs	killer cell immunoglobulin-like receptors;
KLRs	killer lectin-like receptors;
LILRs	leukocyte immunoglobulin-like receptors;
mbIL-21	membrane-bound IL-21;
MDSC	myeloid-derived suppresive cell;
MNC	mononuclear cell;
NHL	non-Hodgkin’s lymphoma;
PB	peripheral blood;
PBMCS	peripheral blood mononuclear cells;
PB-NKs	peripheral blood-derived NK cells;
PD-1	programmed cell death protein 1;
scFv	single-chain fragment variable;
sgp130	soluble glycoprotein130;
sIL-2Rα	soluble interleukin 2 receptor-α;
TAA	tumor-associated antigen;
TAM	tumor-associated macrophage;
TCM	central memory T cell;
TCRs	T cell receptors;
TEM	effector memory T cells;
Th1	T helper 1;
TM	transmembrane domain;
TME	tumor microenvironment;
TN	naive T cells;
TNF-α	tumor necrosis factor-α;
TRAIL	TNF-related apoptosis-inducing ligand;
TRAILR	TRAIL receptor;
Treg	regulatory T cells;
UCB	umbilical cord blood;
UCB-NKs	Umbilical cord blood-derived NK cells